European Neuropsychopharmacology

European Neuropsychopharmacology (Eur. Neuropsychopharmacol.) is published by Elsevier on behalf of the European College of Neuropsychopharmacology and is the college's official journal. Founded in November 1990, it concentrates on the neurobiology of psychiatric disorders and on psychopharmacology, appears monthly, and had a 2025 impact factor of 8.1.《欧洲神经精神药理学》（European Neuropsychopharmacology''''，缩写 Eur. Neuropsychopharmacol.''）是爱思唯尔代表欧洲神经精神药理学学院出版的刊物，1990 年 11 月创刊，为该学院官方刊物。该刊以精神障碍的神经生物学与精神药理学为主，现为月刊，二〇二五年影响因子为 8.1。

Scope

The journal's editorial stance is that brain science has to connect with clinical treatment: in the college's own statement of mission, it is to translate understanding of brain function and human behaviour into better treatment and greater public health impact. Coverage runs from basic mechanism to clinical trial and concentrates on:本刊的取稿立场是「把脑科学与临床治疗连起来」：按该学院的使命表述，本刊要把对脑功能与人类行为的理解转化为更好的治疗与更强的公共卫生影响。收文覆盖从基础机制到临床试验的链条，重点包括：

• Clinical and basic neuropsychopharmacology: mechanisms of drug action and receptor pharmacology, clinical trials of psychotropic drugs, pharmacokinetics and pharmacodynamics, and new targets and drug development.临床与基础神经精神药理学： 药物作用机制与受体药理、精神药物的临床试验、药代与药效、新靶点与新药开发。

• Neurobiology of psychiatric disorders: mechanisms of mood and psychotic disorders, anxiety and stress-related disorders, addiction and reward circuitry, and sleep and circadian rhythms.精神障碍的神经生物学： 情感障碍与精神病性障碍的机制、焦虑与应激相关障碍、成瘾与奖赏回路、睡眠与昼夜节律。

• Psychopharmacology and clinical trials: randomised controlled trials and real-world studies, drug comparisons and sequencing, prescribing strategies in treatment-resistant cases, and safety and tolerability.精神药理学与临床试验： 随机对照试验与真实世界研究、药物比较与序贯治疗、难治性病例的用药策略、安全性与耐受性。

• Neuroimaging and genetics: structural and functional imaging, molecular imaging and receptor visualisation, psychiatric genetics and genomics, and imaging genetics.神经影像与遗传学： 结构与功能影像、分子影像与受体显像、精神疾病遗传学与基因组学、影像遗传学整合。

• Cognition and functional outcome: cognitive function and neuropsychological assessment, social cognition, functional recovery and rehabilitation, and assessment of quality of life.认知与功能结局： 认知功能与神经心理测评、社会认知、功能恢复与康复、生活质量的评价。

• Translation and prevention: early detection and intervention, biomarkers and stratified treatment, prevention strategies, and health services and public health research.转化与预防： 早期识别与干预、生物标志物与分层治疗、预防策略、卫生服务与公共卫生研究。

The journal is hybrid, subscription-based with optional gold open access, and the article processing charge is 3,450 US dollars. The publisher reports an acceptance rate of 15 per cent and forty-five days to a decision after review本刊为混合出版（以订阅为主、可选金色开放获取），文章处理费为三千四百五十美元；出版方公布录用比例为百分之十五、投稿至评审后决定四十五天；另列投稿至录用三十三天，该数值短于评审后决定的四十五天，两者口径不一致，本稿并列写明而不取其一。 it also lists thirty-three days to acceptance, a figure shorter than the forty-five days to a decision after review. The two are inconsistent in basis and both are recorded here without choosing between them.^[1]

History

• Founding (1990): volume 1, issue 1 appeared in November 1990, and the founding editors were Jan M. van Ree of Utrecht University and Stuart A. Montgomery of London, who jointly signed the editorial in the first issue. The rationale was to carry out the college's mission and to close the gap between basic neuroscience and clinical translation.创刊（1990年）： 1990 年 11 月出版第 1 卷第 1 期，创刊主编为（Jan M. van Ree）（荷兰乌得勒支大学）与（Stuart A. Montgomery）（英国伦敦），两人共同署名创刊号的社论；创刊动因是落实该学院使命并填补基础神经科学与临床转化之间的落差。^[2]

• Title and publisher: the journal has used its present name since founding, with no predecessor title and no renaming. It has been published by Elsevier since 1990 with no change of publisher, and now appears monthly, twelve issues a year.刊名与出版方： 本刊创刊即用现名，无前身亦无改名；自 1990 年创刊至今由爱思唯尔出版，无出版方变更记录；现为月刊，每年十二期。^[3]

• Sister title (2024): in 2024 to 2025 the college added a fully open access sister journal, Neuroscience Applied, edited by the former editor Andreas Meyer-Lindenberg, while this journal retained its position as the college's traditional subscription title.姊妹刊（2024年）： 该学院于 2024 至 2025 年间新增完全开放获取的姊妹刊（Neuroscience Applied），由前任主编（Andreas Meyer-Lindenberg）主持；本刊则保持传统订阅刊定位。

• Metrics and indexing: the impact factor is 8.1 and the CiteScore 13.2. The college's own page records the impact factor rising to 8.100 from 6.700. The journal is indexed in the Science Citation Index Expanded, Scopus and MEDLINE.指标与收录： 影响因子 8.1、引用分数 13.2；该学院官方页同步记载影响因子由 6.700 升至 8.100；本刊被科学引文索引扩展版、Scopus 与 MEDLINE 收录。^[1]

Editors

The editor is appointed by the college and there were two joint editors at founding. The present editor comes from Barcelona and is listed as editor of the journal in successive college executive committee lists from 2019 to 2025. The college and the publisher publish no list of intermediate editors.本刊主编由该学院任命，创刊时为两名共同主编；现任主编来自西班牙巴塞罗那，在该学院 2019 至 2025 年间的多届执行委员会名单中均列为本刊主编；中间历任主编名单该学院与出版方官网均未公布。^[4]

• Present editor-in-chief: Eduard Vieta works in the bipolar and depressive disorders unit of the Institute of Neuroscience at the University of Barcelona, Hospital Clínic and IDIBAPS. The year of appointment is not published现任主编： （Eduard Vieta）供职于巴塞罗那大学神经科学研究所（Hospital Clínic / IDIBAPS）双相与抑郁障碍单元；就任年份官网未公布，据该学院年报推定自 2020 年前后起。 on the basis of the college's annual reports it is taken to be around 2020.

• Founding and past editors: the founding joint editors were Jan M. van Ree and Stuart A. Montgomery, in post from 1990. Andreas Meyer-Lindenberg of Heidelberg University was still listed as editor in the college's 2019 annual report, serving to about 2020 before moving to the new journal. The remaining intermediate editors are not published.创刊与历任主编： 创刊共同主编为（Jan M. van Ree）与（Stuart A. Montgomery），自 1990 年起在任；（Andreas Meyer-Lindenberg）（德国海德堡大学）在该学院 2019 年年报中仍列为本刊主编，约至 2020 年卸任并转任新刊；其余中间历任未公布。^[5]

• Role in the field: as the official journal of the European College of Neuropsychopharmacology, the journal is one of the main channels for European evidence from psychopharmacology trials, and its reviews and treatment guidance are widely used in European psychiatric practice.学科角色： 作为欧洲神经精神药理学学院的官方刊物，本刊是欧洲精神药理学临床试验证据的主要发表渠道之一，其综述与治疗指南类文章在欧洲精神科实践中被广泛采用。